Actively Recruiting
A Study of JNJ-1761981 in Participants With Solid Tumors
Led by Johnson & Johnson Enterprise Innovation Inc. · Updated on 2026-05-14
66
Participants Needed
2
Research Sites
141 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.
CONDITIONS
Official Title
A Study of JNJ-1761981 in Participants With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Part 1: Adults with locally advanced or metastatic solid tumors (excluding CNS tumors) who have progressed after, cannot tolerate, or have no standard therapy
- Part 2 Cohort A: Adults with confirmed metastatic adenocarcinoma or squamous cell carcinoma who progressed after platinum-based systemic therapy
- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0 or 1
- For Part 2 Cohort A participants receiving cetrelimab: normal thyroid function tests or on thyroid hormone replacement therapy
- Participants of childbearing potential must use at least 2 highly effective contraception methods during the study and for specified months after last dose of JNJ-1761981 or cetrelimab
You will not qualify if you...
- Active symptomatic disease involving the central nervous system
- Prior or concurrent second malignancy likely to interfere with study safety or treatment activity
- Active bleeding disorders or need for anticoagulation that cannot be adjusted for procedures
- Known allergies or intolerance to JNJ-1761981 or its components
- Tumor lesions invading or near major blood vessels or critical structures unsuitable for injection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Montefiore Medical Center
The Bronx, New York, United States, 10467
Actively Recruiting
2
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here